Shire PLC (SHPG) Position Raised by Mackenzie Financial Corp

Mackenzie Financial Corp boosted its position in Shire PLC (NASDAQ:SHPG) by 28.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,388 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the period. Mackenzie Financial Corp’s holdings in Shire were worth $978,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. YorkBridge Wealth Partners LLC lifted its position in Shire by 81.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 317 shares during the period. Pacer Advisors Inc. acquired a new stake in Shire in the second quarter valued at about $171,000. Stephens Inc. AR lifted its position in Shire by 22.2% in the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 228 shares during the period. Aureus Asset Management LLC acquired a new stake in Shire in the second quarter valued at about $212,000. Finally, Wedbush Securities Inc. lifted its position in Shire by 12.9% in the second quarter. Wedbush Securities Inc. now owns 1,310 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 150 shares during the period. Hedge funds and other institutional investors own 20.28% of the company’s stock.

Shares of Shire PLC (SHPG) opened at $148.00 on Monday. Shire PLC has a 12-month low of $137.17 and a 12-month high of $192.15. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. The stock has a market cap of $44,463.20, a P/E ratio of 10.18, a PEG ratio of 0.82 and a beta of 1.59.

Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company had revenue of $3.70 billion during the quarter. During the same quarter in the previous year, the business posted $3.17 earnings per share. Shire’s revenue was up 7.1% on a year-over-year basis. sell-side analysts anticipate that Shire PLC will post 15 earnings per share for the current year.

A number of brokerages recently commented on SHPG. Evercore ISI began coverage on shares of Shire in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price objective for the company. Royal Bank Of Canada restated a “buy” rating and issued a $213.00 price objective on shares of Shire in a research report on Monday, October 2nd. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Shire in a research report on Sunday, October 8th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Tuesday, December 5th. Finally, Cowen set a $225.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Sunday, October 29th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $212.18.

COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Position Raised by Mackenzie Financial Corp” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/11/shire-plc-shpg-position-raised-by-mackenzie-financial-corp.html.

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply